Cartesian Therapeutics reported financial results for the quarter ended June 30, 2026, on August 6, 2026. The company posted net income of $15.8 million, or $0.47 per share, compared to $15.9 million in the prior year period. Cash and cash equivalents stood at approximately $149.3 million as of June 30, 2026, extending its operational runway into 2028 following a credit facility with K2 HealthVentures. The company provided business updates on its Descartes-08 pipeline, noting that the Phase 3 AURORA trial in myasthenia gravis is advancing with data expected in the first quarter of 2027 and a BLA filing planned for mid-2027. Additionally, Cartesian announced a strategic partnership with WestGene BioPharma to explore an in vivo CAR-T platform, with Phase 1 data anticipated in the first half of 2027. Cartesian Therapeutics is a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases.

On June 9, 2026, Cartesian Therapeutics, Inc. entered into a strategic licensing agreement with WestGene Biopharma Co. to advance the development of in vivo chimeric antigen receptor T-cell (CAR-T) therapies for autoimmune diseases. Cartesian Therapeutics, Inc. is a biotechnology company focused on developing novel cell and gene therapies.